By inducing DNA damage, radiotherapy both reduces tumor burden and enhances antitumor immunity. Here, we review the mechanisms by which radiation induces antitumor immune responses, which can be augmented using immunotherapies to facilitate tumor regression. Radiotherapy increases inflammation in tumors by activating the nuclear factor kB and the type I interferon response pathways to induce expression of proinflammatory cytokines. This inflammation coupled with antigen release from irradiated cells facilitates dendritic cell maturation and cross-presentation of tumor antigens to prime tumor-specific T cell responses. Radiation also sensitizes tumors to these T cell responses by enhancing T cell infiltration into tumors and the recognition of both malignant cancer cells and nonmalignant stroma that present cognate antigen. Yet, these antitumor immune responses may be blunted by several mechanisms, including regulatory T cells and checkpoint molecules that promote T cell tolerance and exhaustion. Consequently, the combination of immunotherapy using vaccines and/or checkpoint inhibitors with radiation demonstrates early clinical potential. Overall, this Review will provide a global view on how radiation and the immune system converge to target cancers and the early attempts to exploit this synergy in clinical practice.
INTRODUCTION
The radiation dose necessary to cause complete tumor regression is often less than the dose expected to kill all of the cancer cells, suggesting that radiation activates other tumoricidal mechanisms. Stone et al. provided early evidence that one such mechanism is the immune system; they found that the radiation dose necessary for tumor control was 1.67-fold higher in immunodeficient mice compared with immunocompetent mice (1) . In support of this finding, Cameron et al. showed that mice treated with tumor-infiltrating lymphocytes (TILs) and focused radiotherapy developed fewer metastatic colonies compared with either treatment individually (2) . Subsequent advances have now provided greater insight into radiation-induced immune responses that are now being used for therapeutic gain. Radiation induces innate and adaptive immune responses against antigenic cancer cells that had pirated immunosuppressive mechanisms to escape destruction.
MODULATION OF TUMOR INFLAMMATION BY RADIATION
Although inflammation is an inherent aspect of cancer development, radiotherapy alters the inflammatory milieu, leading to the maturation of antigen-presenting cells and the activation of antitumor T cells. Hallahan et al. first showed that radiation induced the expression of tumor necrosis factor-a (TNFa) (3) , and subsequent studies have demonstrated that other proinflammatory cytokines including interferon-a (IFN-a), IFN-b, and IFN-g were also induced in irradiated cancer cells (4, 5) . Radiation can activate this cytokine production through two main pathways, the nuclear factor kB (NF-kB) pathway and the type I IFN response pathway (Fig. 1) .
Role of NF-kB in radiation-induced inflammation
The NF-kB pathway is a master regulator of both innate and adaptive immunity. NF-kB is a transcription factor composed of homodimers or heterodimers of the NF-kB/Rel family: RelA (p65), RelB, c-Rel, p50/p105 (NF-kB1), and p52/p100 (NF-kB2). Although NF-kB is activated through both canonical and noncanonical pathways, the end result is the translocation of the NF-kB complex to the nucleus to induce proinflammatory gene expression including TNFa, interleukin-6 (IL-6), IL-1a, and IL-1b, among others. Radiation activates the genotoxic stress arm of the NF-kB pathway through recognition of doublestrand DNA breaks (DSBs) by ataxia telangiectasia-mutated protein (ATM) (6, 7) . After recruitment to DSBs in the nucleus, the ATM complex then translocates to the cytoplasm to activate the p50/p65 complex of NF-kB.
Although radiation induces many proinflammatory cytokines through NF-kB, the overall impact of NF-kB activation in cancer cells remains nebulous because of its paradoxical radioprotective and radiosensitizing effects. Activation of NF-kB may directly prevent cell death by inducing antiapoptotic genes, including the inhibitor of apoptosis protein family members and the TNFa-induced protein 3 (TNFAIP3/A20) that inhibits cell death (8) . NF-kB activation may also induce inflammatory stimuli that promote tumor growth, such as matrix metalloproteinases and vascular endothelial growth factor (VEGF). Although NF-kB activates antitumor immune responses, the complex role of NF-kB in irradiated cancers requires further investigation before this pathway is manipulated for therapeutic gain.
Role of the IFN response pathway in radiation-induced inflammation
Radiation also induces IFN-related genes including IFN-a, IFN-b, signal transducer and activator of transcription 1 (STAT1), and IFN-g (4, 5) . Type I and type II IFN responses play predominant roles during distinct phases of antitumor immunity. In cancers, secretion of the type I IFNs, IFN-a, and IFN-b facilitates dendritic cell (DC) maturation that is necessary for the generation of effector T cells (9) , which return to the tumor to secrete the type II IFN, IFN-g, to cause vascular destruction and to sensitize tumors to cytolytic T cells. Burnette et al. showed that type I IFN was essential for the rejection of antigenic melanoma cells after a single fraction of 25 grays (Gy) (4) . Furthermore, radiation induced IFN-b, causing DC maturation that led to the induction of effector CD8 + T cell responses against antigenic tumors. Lugade et al. showed that neutralization of IFN-g potentiated the growth of B16 melanoma tumors after 15 Gy (5). Here, loss of IFN-g sensitivity led to decreased recognition of antigenic tumor cells by effector T cells and decreased vasculature destruction.
To induce type I IFN in cancer cells, radiation likely co-opts intracellular viral sensing pathways involving cytosolic sensors such as the stimulator of interferon genes (STING), retinoid acid-inducible gene 1 (RIG1), melanoma differentiation-associated protein 5 (MDA5), and laboratory of genetics and physiology 2 (LGP2). Initially described in innate antiviral responses, several groups have shown that STING responds to cytosolic DNA and possibly RNA that is present during viral infections (10, 11) . Cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) synthase recognizes cytosolic DNA and produces cGAMP(2′-5′) that, in turn, activates STING. STING induces IFN gene expression by activating IFN regulatory factor 3 (IRF3) and by inducing other STAT6-dependent proinflammatory genes. Radiation also likely induces type I IFN responses by inducing the accumulation of cytosolic DNA. Deng et al. reported that STING was necessary for radiation-induced IFN responses; radiation failed to stimulate the maturation of intratumoral DCs in mice with STING loss (12) . Furthermore, exogenous cGAMP promoted antitumor immune responses against irradiated tumors and enhanced tumor regression. In addition, RIG1, MDA5, and LGP2 are RNA sensors that act through IRF3 and NF-kB to induce proinflammatory cytokines. Radiation also activates these RNA sensors, which have been shown to be necessary for the induction of type I IFN after DNA damage (13) . In addition to being directly produced by irradiated cells, it is likely that secondary messengers such as cGAMP are transferred through gap junctions to stimulate the STING pathway in nonirradiated cells (14) .
Similar to the NF-kB pathway, the activation of the interferon response pathway after radiation may play paradoxical protumorigenic and antitumorigenic roles. Although acute activation of the IFN pathway by radiation is cytotoxic, chronic activation of the IFN/STAT1 pathway makes cancers radioresistant (15, 16) and is associated with worse outcomes after radiotherapy and/or chemotherapy (17) .
RADIATION MODULATES THE PRIMING OF ADAPTIVE IMMUNE RESPONSE AGAINST TUMORS
Radiation induces immunologic cell death DNA damage, such as that induced by radiation, often leads to cell death through either apoptosis or necrosis. Apoptosis and necrosis differently affect the generation of immune responses against tumors (Fig. 2) . Antigens from apoptotic cells are more efficiently crosspresented by DCs, likely because of the membrane translocation of calreticulin and phosphatidylserine and other ligands that facilitate DC phagocytosis (18) . However, phagocytosis of apoptotic cells is not sufficient for DC maturation and T cell priming. White et al. demonstrated that the activation of caspase-3/7, apoptotic protease activating factor 1, and caspase-9 during apoptosis prevented the induction of a STING-dependent type I IFN response (19) . Instead, Sauter et al. demonstrated that necrotic tumor cells were necessary to mature DCs that then primed CD8 + T cells (20) . Necrotic cells release a high-mobility group B1 protein that induces DC maturation through an NF-kB pathway. Because radiation induces cell death via apoptosis and/or necrosis, radiation likely helps to prime antitumor immunity by increasing antigen release by cancer cells, increasing antigen uptake by DCs, and increasing DC maturation.
Radiation enhances cross-presentation of antigen
Compared with direct presentation, cross-presentation requires a higher concentration of antigen to be acquired and processed by DCs (Fig. 2) (21) . Radiation-induced cell death likely causes the release of antigens that is sufficient to exceed the threshold necessary for cross-presentation by DCs (22) . For antigens already expressed at levels sufficient for cross-presentation, Lugade et al. demonstrated that radiation further increased the number of DCs presenting antigen, likely due to the release of antigen from dying cells (23) . The release of antigen at sufficient levels for cross-presentation likely depended on the fraction size and total dose. Lee et al. demonstrated that a single dose of 20 Gy induced T cell proliferation in the draining lymph node (DLN) and tumor regression, whereas 20 Gy given in four fractions was significantly less effective in inhibiting tumor growth (24) . Although there is little systematic assessment for how different fractionation schemes enhance antigen presentation, several groups suggest that fraction sizes of 7.5 Gy or higher were necessary to facilitate antigen cross-presentation (25, 26) . However, many of these studies have used peptide antigens with major histocompatibility complex (MHC) affinities of less than 10 nM, which may overestimate the capacity of radiation to facilitate the cross-presentation of physiologically relevant antigens that have substantially lower peptide-MHC affinities. Thus, the ability of radiation to stimulate immune responses to immunologically ignored cancer antigens likely depends on antigen expression level and its MHC affinity.
In addition to increasing antigen release from dying cells, radiation may also alter the peptide repertoire available for antitumor immune responses. First, radiation may induce the expression of normally silent genes that serve as neoantigens. Using high-performance liquid chromatography to identify MHC-binding proteins eluted from irradiated cells, Reits et al. demonstrated that radiation induced the expression of proteins that were not normally presented by MHC molecules (27) . Sharma et al. also demonstrated that a single dose of 20 Gy induced the expression of normally silent cancer testis antigens in various cancer cell lines and in sarcoma biopsies (28) . In addition, radiation-induced inflammatory responses may alter the processing and presentation of peptide epitopes by the formation of an IFN-induced immunoproteasome. Morel et al. demonstrated that the immunoproteasome processes cellular antigens in mature DCs differently compared with the standard proteasome (29) . These radiation-inducible genes may also serve as antigens for antibody-targeted therapy. Yan et al. developed a monoclonal antibody, 2C6F3, that recognizes radiationinducible Tax-interacting protein-1 (30) . Binding of 2C6F3 to irradiated cancer cells promoted antibody-dependent cell-mediated cytotoxicity and phagocytosis, and a radiolabeled 2C6F3 inhibited tumor growth in vivo. Thus, radiation may facilitate antigen presentation by increasing the quantity and quality of antigen available for cross-presentation.
Radiation induces DC maturation
Once DCs acquire antigen, these cells must mature to traffic to the DLN to initiate an immune response (Fig. 2) . Gupta et al. demonstrated that high-dose irradiation of B16 melanoma caused DC maturation that was necessary for CD8 + T cell priming (31) . Antigens released by cell death were not sufficient to stimulate T cell priming because melanoma cells that were engineered to die under noninflammatory conditions failed to induce antitumor immune responses. Rather, local irradiation caused DC maturation, as measured by the increased expression of the costimulatory molecules CD70 and CD86 in DCs. In both mouse models and human tumors, CD70 expression in mature DCs was necessary for effective T cell priming against irradiated tumors because CD70 blockade inhibited T cell priming and regression of irradiated tumors (31, 32) .
Although many cancers are prone to lymphatic spread, the radiation dose used in elective nodal irradiation to sterilize microscopic disease also likely suppresses effective antitumor immune responses. Pelvic irradiation to 39.6 Gy likely induced antitumor immune responses as CD4 + and CD8 + T cells demonstrated increased T helper 1 and T cytotoxic 1 phenotypes (33) . By contrast, DLN irradiated to a higher dose of 50 Gy demonstrated suppressed effector T cell responses, indicating that elective nodal irradiation impaired the generation of antitumor immune responses in a dose-dependent manner. Consequently, the immunological benefits of radiotherapy more likely occur in scenarios where only the primary tumor is irradiated, such as stereotactic body radiotherapy (SBRT).
RADIATION MODULATES EFFECTOR T CELL RESPONSES Radiation increases T cell infiltration
During the effector phase of the immune response, radiation may facilitate the immunological rejection of tumors by inducing chemokine expression that recruits cytotoxic CD8 + T cells into tumors (Fig. 3) . Matsumura et al. demonstrated that radiation up-regulated the chemokine C-X-C motif chemokine ligand 11 (CXCL16) in murine cancer cells that facilitated T cell recruitment into irradiated tumors to enhance tumor regression in combination with immunotherapy (34) . In addition, Meng et al. demonstrated that radiation also induced the expression of C-C motif chemokine ligand 3 (CCL3), CCL4, CCL5, CXCL9, CXCL10, and CXCL11 (35) .
Radiation therapy may also facilitate T cell infiltration by altering the vascular phenotype (Fig. 3) . The ability of radiotherapy to facilitate T cell infiltration is due to vascular normalization and the induction of inflammatory cytokines including IFN-g and/or TNFa. Tumors often display a disorganized vasculature that normalizes after treatment with antiangiogenic agents such as VEGF inhibitors. This normalization of the vasculature by antiangiogenic agents facilitates lymphocyte infiltration and enhances tumor regression (36) . Similarly, Ganss et al. demonstrated that a single dose of 10 Gy facilitated the infiltration of antigen-specific T cells into primary insulinomas (37) . Notably, the normalization of the tumor vasculature may persist even after completing treatment because antigen-specific T cells displayed increased tumor infiltration even 3 weeks after tumor irradiation.
The ability of radiotherapy to recruit T cells to tumors may be particularly important for tumors with a non-T cell-inflamed phenotype. Recent work in melanoma has prompted the classification of cancers by a T cell-or a non-T cell-inflamed phenotype based on the presence or absence of TILs, respectively (38) . The T cell-inflamed phenotype predicts improved responses to programmed death 1 (PD-1)-PD ligand 1 (PD-L1) checkpoint blockade. Because the checkpoint blockade fails in most of the patients, increasing T cell infiltration into non-T cell-inflamed tumors may improve outcomes. To this end, Tang et al. demonstrated that targeting the TNF superfamily member LIGHT increased T cell infiltration and sensitized non-T cell-inflamed tumors to PD-L1 therapy (39) . Similarly, other proinflammatory agents, such as CpG oligonucleotides, also enhanced the extravasation of T cells into tumors, suggesting that inflammatory environments may facilitate a T cell-inflamed phenotype. As an extension, the ability of radiotherapy to promote inflammation and recruit T cells into tumors may help sensitize cancers that are otherwise resistant to PD-L1 therapy.
Radiation facilitates effector T cell recognition of antigenic tumors
Radiation also facilitates the recognition and killing of tumor cells by effector CD8 + T cells by increasing the recognition of irradiated cancer cells that have a lower threshold for being killed by cognate T cells (Fig. 3) . In both in vitro and in vivo models, radiation induced MHC expression on cancer cells that facilitated the recognition of antigenic cancer cells by T cells (26, 28, 40) . The up-regulation of MHC by radiation was likely due to the induction of type I IFN after radiation. Furthermore, radiation doses as low as 2 Gy induced MHC upregulation on cancer cells, indicating that conventional fractionation likely facilitates the immunological recognition of antigenic cancer cells. To sensitize cancer cells to killing by cytotoxic T cells, radiation up-regulated the expression of the cell death ligand Fas in multiple murine and human cancer cell lines (41, 42) . Notably, Fas expression persisted for longer than 11 days after radiation, suggesting that effector T cells may recognize irradiated tumors for several weeks after completing treatment. Yet, it remains unclear whether conventional fraction sizes (about 2 Gy) are sufficient to induce Fas expression because previous studies only used radiation doses of 8 Gy or higher.
In addition to increasing direct recognition and killing of antigenic cancer cells, radiation may also enhance the immunologic recognition and destruction of the tumor stroma that is essential for tumor growth (Fig. 3) . Stromal cells that cross-present tumor antigens also become targets for cytotoxic T cells, resulting in the indirect killing of antigenic cancer cells, a process that can be facilitated by radiation (22, 43) . Similarly, Wu et al. loaded the stroma with intratumoral injection of exogenous antigen to facilitate the immunological rejection of irradiated tumors (44) . Thus, radiation may facilitate the immunological destruction of tumors by sensitizing both malignant cancer cells and nonmalignant stromal cells to killing by cytotoxic T cells.
Radiation facilitates NK cell recognition of tumors
Although radiation facilitates the specific recognition of antigenic cancer cells by cytotoxic CD8 + T cells, cancer cells that have lost MHC may escape radiation-induced, immune-mediated rejection. As an immunosurveillance mechanism against the loss of antigen presentation or 
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Tumor-associated myeloid cells (56) . However, it remains unclear whether radiotherapy directly caused the loss of MDSCs or whether radiation induced T cell infiltration, leading to MDSC elimination. By contrast, irradiated tumors displayed increased macrophage infiltration likely via the up-regulations of the chemoattractants stromal cell-derived factor 1 (SDF-1) and colony-stimulating factor 1 (CSF-1) as well as the SDF-1 receptor C-X-C chemokine receptor type 4 (57-59). Increased TAM influx promotes tumor growth because macrophage neutralization using CD11b-blocking antibodies protected irradiated tumors and was associated with increased vasculogenesis and/or matrix metalloproteinase expression (57, 60, 61) . Radiation may also promote an M1 macrophage phenotype because multiple fractions of 1 to 2 Gy induced nitric oxide synthase in TAMs, resulting in vascular remodeling and the recruitment of effector CD8 + T cells (62) . However, the ability of radiation to promote M1 or M2 TAM phenotypes is likely influenced by the host's genotype (63) . Thus, myeloid cells protect irradiated tumors both directly by fostering a progrowth environment and indirectly by inhibiting antitumor immune responses.
Regulatory T cells Regulatory T cells (T regs ) are a subpopulation of T cells that abrogates
antitumor immune responses to self-antigens. Unlike immune responses that were often specific to unique tumor antigens, T regs likely react against common self-antigens because a single population of "suppressor" cells inhibited immune responses against multiple tumor types (64) . T regs have been defined by the cellular markers CD4, CD25, and Foxp3. Because many lymphocytes at various stages of activation express these markers, it is difficult to specifically identify T regs without functional assays.
Radiation increases the numbers of T regs in tumors that likely depend on the radiation dose (26, 65) . Consequently, efforts to deplete T regs may enhance the effectiveness of radiotherapy by increasing antitumor immunity. Depletion of T regs using an anti-CD25 antibody, PC61, augmented radiation-induced antigen-specific immune responses, enhanced tumor regression of irradiated tumors, and improved survival in murine models (26, 65) . Because activated T cells also express CD25, the widespread use of this approach may also negate the benefit of radiation-induced antitumor immune responses. In humans, the most suppressive T cells, CD45RA − FOXP3 hi CD4 + T cells, specifically express C-C motif chemokine receptor 4 (CCR4). Sugiyama et al. demonstrated that anti-CCR4 antibody treatment reduced T regs and potentiated NY-ESO1-specific CD8 + T cell responses in cancer patients (66) . Consequently, it is interesting to speculate whether anti-CCR4 antibody may also enhance radiation-induced immune responses in humans.
Immunological checkpoints
Many preclinical insights into augmenting radiation-induced antitumor immune responses have focused on combining checkpoint agonists and antagonists with radiation (Fig. 4) . Immune checkpoints are molecules (such as costimulatory molecules) that enhance or inhibit immune responses. The two most widely studied checkpoints are cytotoxic T lymphocyte antigen-4 (CTLA-4) and PD-1. Expressed on helper CD4 + T cells, CTLA-4 binds to CD80 (B7-1) or CD86 (B7-2) on antigen-presenting cells to inactivate helper T cells and mitigate the expansion of effector CD8 + T cells (67, 68) . PD-1 is expressed on effector T cells and binds to the ligands PD-L1 or PD-L2 expressed on DCs, stromal cells, and some cancer cells to induce apoptosis in effector T cells and exhaust antitumor immune responses.
The use of radiation with PD-L1 and CTLA-4 inhibitors has been extensively studied. Demaria et al. demonstrated that CTLA-4 combined with radiation improved survival in tumor-bearing mice as a result of reduced lung metastases but had minimal effect on the growth of irradiated tumors (69) . In this model, invariant NK (iNK) T cells likely inhibited the regression of irradiated tumors because tumors regressed in 50% of mice deficient in iNK T cells (70) . In other models, radiation and CTLA-4 blockade also inhibited the growth of irradiated tumors by arresting TIL motility and increasing TIL accumulation to facilitate tumor cell killing via NKG2D up-regulation (71) . Similarly, Deng et al. demonstrated that PD-1 inhibition synergized with radiation by blocking PD-L1 on both cancer cells and myeloid stromal cells, causing a reduction of MDSCs in the tumor microenvironment (72) . Moreover, Sharabi et al. showed that high-dose radiotherapy synergized with PD-1 inhibition by blocking local suppression of antitumor immune responses that were stimulated by radiation (26) . PD-1 inhibition may reverse the up-regulation of PD-L1 expression on cancer cells induced by radiation (73) . Several additional tumor models including gliomas, colon cancers, and breast cancers have been used to confirm the synergism between PD-1 blockade and radiation (73, 74) . Last, radiation may benefit from combinatorial checkpoint blockade where radiation improved antigen presentation, CTLA-4 blockade promoted T cell expansion, and PD-1 blockade prevented T cell exhaustion (75) .
In addition, there are other checkpoints that may be targeted with radiation to enhance antitumor immune responses to achieve improved cancer control. Radiation combined with checkpoint activators including OX40 and 4-1BB prevented T cell exhaustion and facilitated the regression of irradiated tumors (76, 77) . Similarly, targeting inhibitors of T cell function, such as transforming growth factor-b (TGF-b) and indoleamine 2,3-dioxygenase, also facilitated the regression of irradiated tumors (77) (78) (79) (80) .
Organ-induced immune tolerance
The spleen likely regulates antitumor immunity because splenectomy enhanced tumor regression that was associated with loss of intratumoral CCR2 + monocytes and activation of CD8 + CTLs (81). Consistent with this observation, Ugel et al. demonstrated that the peripheral tolerance to tumor antigens in the spleen was mediated by CCR2 + monocytes that cross-presented antigen into order to tolerize memory CD8 + T cells (82) . Because splenic irradiation is essentially nontoxic, it is interesting to speculate whether irradiating the spleen would augment immunotherapy. To this end, Aalbers et al. demonstrated that 6-Gy local splenic irradiation caused an abscopal effect in four patients with chronic myelogenous leukemia (83) .
In addition, the presence of metastasis in the central nervous system may also adversely affect the ability of radiation to stimulate antitumor immune responses. Using a B16 melanoma model, Jackson et al. demonstrated that melanoma brain metastases induced greater CD8 + T cell tolerance compared with peripheral tumors (84) . Radiation of brain metastases coupled with vaccination against tumor antigens reversed immune tolerance and improved survival.
Other factors that potentially modulate radiation-induced antitumor immunity Other variables including the cancer's genetic landscape, the patient's age, and the enteric flora can affect immune responses and modulate the effectiveness of radiotherapy. Because the genomic landscape of cancer cells correlates with cytolytic T cell signatures, it is likely that the genetic profiles of tumors also dictate radiation-induced immune responses and, therefore, could be used to guide the selection of patients for combined radiotherapy and immunotherapy protocols. (85) . Age is associated with both an increasing cancer incidence and impaired immunity (86) . Consequently, T cells from young mice, but not aged mice, rejected established tumors expressing immunodominant antigens (87) . Therefore, attempts to rejuvenate aged immune responses may rescue a senile immune system and potentially benefit older patients undergoing radiotherapy. Last, the gut flora can regulate local and systemic inflammation and, consequently, immune responses against tumors (88, 89) . Because radiation also alters the inflammatory tumor microenvironment, the impact of oral and gastrointestinal flora may influence radiation-induced immune responses against tumors.
CLINICAL APPLICATIONS OF IMMUNOTHERAPY WITH RADIATION
The clinical implementation of immunotherapy with radiation is currently limited to patients with metastatic disease because of the potential of minimally toxic radiation doses to induce an abscopal response. The abscopal response is systemic and causes the regression of nonirradiated lesions with localized radiotherapy [reviewed by Siva et al. (90) ] and, consequently, may lead to improved disease-free and overall survival in cancer patients.
Radiation combined with tumor vaccines and adjuvants
Vaccines include peptide-based vaccines, recombinant viral-based vaccines, and antigen-loaded DC-based vaccines. In prostate cancer patients, a recombinant TRICOM vaccine against prostate-specific antigen (PSA) combined with localized prostate radiotherapy induced antigen-specific T cell responses in irradiated patients (91) . Recently, a DC-based vaccine, sipuleucel-T, has been approved in patients with metastatic prostate cancer (92) , and the combination of this vaccine with radiotherapy is being tested in clinical trials.
In addition, combining Toll-like receptor (TLR) agonists with radiation may potentiate antitumor immune responses. TLRs are pattern recognition receptors on antigen-presenting cells that bind ligands present in pathogenic organisms to induce DC maturation. In 15 patients with low-grade non-Hodgkin's lymphoma, Brody et al. Table 1 . Selected ongoing clinical studies of vaccines in combination with radiation. A search of ClinicalTrials.gov was performed in April 2016 for "interventional studies," "vaccine and radiation," "open studies," and "immunotherapy and radiation," retrieving 271 records. Selected studies were reviewed for inclusion in this summary table based on the authors' perception of the size and overall impact of the trial. ERBT, external beam radiotherapy; EORTC, European Organisation for Research and Treatment of Cancer; ADCC, antibody-dependent cell-mediated cytotoxicity; mFOLFIRINOX, modified FOLFIRINOX; bPFS, biochemical progression-free survival; NCI, National Cancer Institute. combined radiotherapy with the TLR-9 agonist PF-351676, resulting in one complete response and three partial responses (93) . Radiotherapy has also been combined with systemic or intratumoral cytokines that promote T cell priming and/or survival. In a phase 1 trial, Seung et al. treated patients with renal cell carcinoma or melanoma metastases with SBRT followed by high-dose IL-2, resulting in response rates that were substantially better than historical controls (94) . However, the widespread use of IL-2 is limited, given the toxic vascular effects that often require hospitalization. In addition, Golden et al. combined radiotherapy with intratumoral injection of granulocyte-macrophage CSF (GM-CSF), a cytokine that promotes DC maturation (95) . Of the 41 patients treated, 26.8% had responses at nonirradiated lesions, suggesting a potential abscopal effect; however, this treatment did not affect the outcomes. Table 1 lists ongoing trials that combine various vaccines with radiotherapy.
ClinicalTrials
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Checkpoint blockade synergizes with radiotherapy
On the basis of the preclinical observations using checkpoint inhibitors with radiotherapy, the initial clinical translation of these approaches has begun. The clinically approved checkpoint inhibitors include ipilimumab that targets CTLA-4, nivolumab and pembrolizumab that target PD-1, and atezolizumab that targets PD-L1. Postow et al. described a patient with metastatic melanoma treated with ipilimumab and SBRT to a single lesion, resulting in regression at Table 2 . Selected ongoing clinical studies of immune checkpoint blockade with radiation. An advanced search of ClinicalTrials.gov was performed in April 2016 for "interventional studies" and "PD-1 and radiation" (retrieved 34 records), "PD-L1 and radiation" (retrieved 29 records), and "immunotherapy and radiation" (retrieved 207 records). These were reviewed for inclusion in this summary table and were selected based on the authors' perception of the size and overall impact of the trial. mAb, monoclonal antibody. both irradiated and nonirradiated lesions that persisted for at least 10 months (96), although it remains unclear whether this therapy stimulated antigen-specific CD8 + T cell responses. Similarly, Hiniker et al. described a patient with multiple metastases treated with ipilimumab and SBRT that also displayed a complete response that persisted for at least 1 year (97) . Last, the benefits of radiotherapy and checkpoint blockade also extended to other cancer types, including non-small cell lung cancers (NSCLCs) (98) .
The addition of radiotherapy to checkpoint blockade likely improves outcomes in patients having specific favorable factors. In a randomized trial, one fraction of 8 Gy to a single bone metastasis enhanced the activity of ipilimumab in patients with castrate-resistant metastatic prostate cancer (99) . Although there was no difference in overall survival between ipilimumab and placebo, an unplanned analysis identified three favorable risk factors: alkaline phosphatase that is <1.5 times than normal, hemoglobin concentration >11 g/dl, and the absence of visceral metastases associated with improved survival. Yet, the efficacy of the ipilimumab with radiotherapy is tempered by increased toxicity and early deaths that were attributed to immunemediated events.
Clinical trials testing the combination of radiation and PD-1/PD-L1 inhibition have been initiated, but no results have been reported. Extrapolating from trials that compare PD-1 blockade to CTLA-4 blockade suggests that the combination of radiotherapy with PD-1 blockade will have a similar, if not better, therapeutic potential compared to radiation and CTLA-4 blockade. In advanced melanoma, the KEYNOTE-006 trial that compared PD-1 blockade to CTLA-4 blockade found that patients treated with PD-1 had better clinical responses (33.7% versus 11.9%), improved progression-free survival (47.3% versus 26.5% at 6 months), and improved overall survival (74.1% versus 58.2% at 6 months) (100). Furthermore, PD-1 blockade was associated with less toxicity (13.3% versus 19.9%).
Yet, much study remains to be done to define the role of radiation with checkpoint blockade. First, the immune-mediated toxicities of combined radiotherapy and checkpoint blockade remain unclear. The more common toxicities associated with checkpoint inhibition include increased dermatitis, pneumonitis, and gastrointestinal and endocrine toxicities (101) . Second, the impact of radiation fractionation on the activity of checkpoint inhibitors remains unclear. Silk et al. suggested that a single high-dose fraction using stereotactic radiosurgery and ipilimumab improved the median survival of patients with brain metastases compared with those treated with conventionally fractionated radiotherapy (102) . Last, the optimal strategy to incorporate radiation with one or multiple checkpoint inhibitors has not yet been determined. Table 2 lists ongoing trials that combine various checkpoint inhibitors with radiotherapy.
Radiation enhances adoptive T cell transfer
Radiotherapy also augments the effectiveness of adoptive T cell therapy. The response rates for adoptive transfer of patient-derived TILs range between 20 and 40%. However, the expansion of these adoptively transferred T cells is regulated by homeostatic mechanisms to maintain the total size of the T cell pool at near-constant levels (103) . Because radiation causes lymphodepletion, total body irradiation (TBI) has been used to augment the expansion of adoptively transferred CD8 + T cells to facilitate tumor rejection (104) . In patients with metastatic melanoma, TBI and adoptive transfer of TILs resulted in response rates as high as 50 to 72%, a substantial improvement over previous TIL strategies (105) .
CONCLUSIONS AND FUTURE DIRECTIONS
The immune system and cellular responses to radiation intersect at multiple points to facilitate tumor eradication. Radiation activates inflammatory pathways, facilitates DC maturation, increases T cell priming, and sensitizes tumor cells to immune recognition. Yet, cancers have also co-opted self-protective mechanisms to suppress or prevent antitumor immune responses that may also intersect with radiation resistance pathways. In the future, tailoring immunotherapy with radiotherapy may involve subverting immune tolerance and/or immune suppression by targeting immunological checkpoints, immunosuppressive cells such as T regs and/or MDSCs, and organs that facilitate immune tolerance. Furthermore, identification of antigens that are important for immune rejection and neo-antigens that arise after radiation may serve as additional targets for the immunotherapy of irradiated tumors. In addition, clinical trials are currently incorporating small molecules such as histone deactylase inhibitors that both sensitize cancer cells to radiation and protects tumor-specific lymphocytes from radiation by facilitating DNA repair (106, 107) . Thus, the role of the immune system in irradiated tumors is being increasingly understood and exploited for therapeutic gain.
